Table 1.

Percent responders to M. leprae peptides measured by lymphocyte proliferation and IFN-γ secretiona

Peptideb% Respondersc in assay of subject typePutative functiondNo. of amino acid mismatches with equivalent M. tuberculosis sequence
LTTIFN-γ
Leprosy exposed or infectedNonexposed and noninfected (United Kingdom)Leprosy exposed or infectedNonexposed and noninfected (United Kingdom)
Group 1
 E897720290DNA polymerase III2/15
 P897260490ATP synthase gamma chain2/15
Group 2
R9022 0 0 32 10 RecA 10/15
Q9021 10 10 56 5 URF 9/15
E8980 7 0 20 10 ABAT 9/15
S9048 16 5 39 5 Serine-rich antigen 8/15
P8975 0 5 46 0 AOS 7/15
E8990 9 0 27 10 AOS 5/15
 K8988202010AOAT4/15
 E897820275DNA polymerase III4/15
 E8983902910HemK protein homologue3/15
 I9073160425ATP-dependent Clp protease1/17
 I90652203310Aspartyl-tRNA synthetase1/15
 K898250275Aminoglucosamine-F-P-transferase1/15
 E8973225240AOAT1/15
 S9061190395SecF1/15
 D89461004010Putative ATPase0/16
 Q9019120485Rho0/15
 D89592004710Putative ATPase0/15
 E898740245ATP binding protein0/15
 E89761102210DNA polymerase III0/15
 R902400115RecA0/15
Group 3
I9063 18 5 40 15 Serine-rich antigen 11/15
I9070 10 20 46 10 Hypothetical 15-kDa protein 11/15
Q9008 18 15 49 30 ATP binding protein 10/15
K8948 5 5 25 55 URF 8/15
S9047 19 15 43 55 Serine-rich antigen 7/15
D8957 5 20 39 10 Putative ATPase 6/15
D8963 12 20 37 30 Alanine racemase 5/15
K8941 3 5 25 15 70-kDa antigen 5/15
S9062 16 5 36 25 Serine-rich antigen 5/15
 P89656104615ATPase synthase alpha chain4/15
 P895612155415ATP synthase gamma chain4/15
 E89924103125DNA polymerase III4/15
 S905823104030SecD3/15
 P896718255165ATPase synthase alpha chain2/15
 S90459153720SecF2/15
 Q900010205245ATP binding protein1/15
 D894410104980ATPase1/15
 S904616103015SecF1/15
 Q898612155435ATP binding protein0/15
 Q898517105125ATP binding protein0/15
 S905719204235SecD0/15
 K89586253165ATPase0/15
  • a Boldface indicates peptides having amino acid mismatches with M. tuberculosis sequences of 5 or more of 15.

  • b Group 1, peptides inducing responses in leprosy-exposed or -infected subjects but not in United Kingdom donors; group 2, peptides inducing stronger responses in leprosy-exposed or -infected subjects than in United Kingdom donors; group 3, peptides inducing good responses in both leprosy-exposed or -infected subjects and United Kingdom donors.

  • c The numbers of leprosy-exposed or -infected subjects tested varied according to the peptide used and are indicated by the peptide prefix as follows: D, 51 and 57; E, 45 and 45; I, 51 and 57; K, 65 and 83; P, 17 and 35; Q, 60 and 84; R, 20 and 38; and S, 43 and 67 for LTT and IFN-γ assays, respectively. Twenty nonexposed and noninfected United Kingdom controls were tested for both the LTT and IFN-γ assays. LTT and IFN-γ were measured following PBMC stimulation with peptide for 5 days. Percent responders were defined as having an SI of ≥2 with a Δ counts per minute of ≥2,000 or ≥50 pg of IFN-γ per ml.

  • d Abbreviations: ABAT, aminobutyrate aminotransferase; AOS, amino-oxononanoate synthase; AOAT, amino-oxononanoate aminotransferase.